ArticleFrontiers in pharmacology2019

Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy.

Rajesh K Kasam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.